IL6 and neoplasm: Following these discoveries, blocking IL-6 signaling gained momentum in the field and yielded positive preliminary findings in animal models; a combination of PD-L1 blockade and IL-6 inhibition could effectively suppress tumor progression and enhance overall survival in murine models of PDAC, which gave rise to a clinical trial (NCT04191421) adopting a similar approach.